These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29283786)

  • 1. Comparison of Efficacy and Safety of Loteprednol Etabonate 0.5% and Topical Dexamethasone 1% in Post-Vitrectomy Inflammation.
    Bilgin AB; Dogan ME; Ayaz Y; Apaydin KC
    Ocul Immunol Inflamm; 2019; 27(2):312-318. PubMed ID: 29283786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy.
    Thanathanee O; Sriphon P; Anutarapongpan O; Athikulwongse R; Thongphiew P; Rangsin R; Suwan-apichon O
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):165-8. PubMed ID: 25555173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
    Holzer MP; Solomon KD; Sandoval HP; Vroman DT
    J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD; Comstock TL; Cavet ME
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
    Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
    Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
    Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
    Al-Awadi A; Tokko HA; Chan CC; Somani S
    Can J Ophthalmol; 2019 Jun; 54(3):388-394. PubMed ID: 31109481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C; Keam SJ; Shirley M; Syed YY
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
    Fong R; Silverstein BE; Peace JH; Williams JI; Vittitow JL
    J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS; Holland EJ
    J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis.
    Comstock TL; DeCory HH
    Ocul Immunol Inflamm; 2017 Apr; 25(2):267-274. PubMed ID: 26788833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO; Feng MT; Scanameo A; Price FW
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
    Rajpal RK; Fong R; Comstock TL
    Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.